ScreenerHero

PHIOPhio Pharmaceuticals Corp.

NAS · US · Healthcare · Biotechnology · phiopharma.com
1.180USD+2.61%Mkt Cap: 13.71M $P/E: —

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap13.71M $
Enterprise Value1.06M $
Revenue (TTM)—
Gross Profit-8.53M $
Net Income (TTM)-8.70M $
Revenue/Share—
Last Price1.180 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.92
PEG—
EV/EBITDA-0.08
EV/Revenue—
P/S—
P/B0.85
EPS (TTM)-1.37
EPS (Forward)-0.63
52W Range
0.813011% of range4.190
52W High4.190 USD
52W Low0.8130 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-43.17%
ROA-40.48%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.98M $
CapEx (TTM)12.00K $
FCF Margin—
FCF Yield-56.35%
Net Debt-13.00M $
Net Debt/EBITDA0.96
Balance Sheet
Debt/Equity—
Current Ratio8.39
Quick Ratio7.62
Book Value/Sh1.417 USD
Cash/Share1.119 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 15, 2020
Splits
Last Split1:9
Split DateJul 5, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.00 USD
Upside (mean)+1086.4%
Target Range14.00 USD – 14.00 USD
# Analysts1
Ownership
Shares Out.11.62M
Float11.53M
Insiders3.82%
Institutions10.21%
Short Interest
Short Ratio0.2d
Short % Float2.48%
Short % Out.2.47%
Shares Short287.35K
Short (prev mo.)218.72K
Technical
SMA 501.045 (+12.9%)
SMA 2001.147 (+2.9%)
Beta0.79
S&P 52W Chg18.16%
Avg Vol (30d)1.06M
Avg Vol (10d)187.96K
Technical Indicators
RSI (14)64.8
MACD0.0238
MACD Signal0.0119
MACD Hist.+0.0119
BB Upper1.153 USD
BB Middle1.063 USD
BB Lower0.9743 USD
BB Width16.76%
ATR (14)0.0616 USD
Vol Ratio (20d)0.98x